Exact Sciences

Exact Sciences is a biotechnology and medical diagnostics firm founded in 1995, specializing in the development and commercialization of non-invasive cancer screening and diagnostic solutions. The company focuses on early detection through advanced molecular diagnostic tests, including its flagship Cologuard product for colorectal cancer screening. By leveraging genomic testing and DNA-based analysis, Exact Sciences provides healthcare providers and patients with actionable clinical data to facilitate informed decision-making. The firm operates at the intersection of biotechnology and medical device manufacturing, maintaining a robust pipeline of diagnostic innovations designed to improve patient outcomes across various oncology segments.

The organization maintains a significant operational footprint with 21 locations globally, supporting its research, development, and manufacturing activities. Learn about Exact Sciences's global headquarters for geographic details regarding their primary facility in Madison, Wisconsin. With a workforce of 5,000-10,000 employees, the company integrates complex laboratory operations with large-scale diagnostic testing capabilities. This infrastructure enables the firm to scale its molecular diagnostic services effectively, ensuring high-throughput processing for routine medical care and specialized genomic testing requirements. The company’s operational model emphasizes precision, reliability, and accessibility in the delivery of life-changing diagnostic insights.

Financially, Exact Sciences demonstrates strong market presence, reporting annual revenue of $3.2B. Meet Exact Sciences's team to learn about their leadership and organizational structure, or Explore financial highlights for detailed metrics. The company competes with major industry players such as Illumina and Natera, positioning itself as a leader in the cancer diagnostics market. Through continuous investment in biotechnology and diagnostic innovation, the firm maintains its competitiveView more...